Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8623734 | Seminars in Arthritis and Rheumatism | 2018 | 6 Pages |
Abstract
Tocilizumab, IV GC and methotrexate improve the likelihood of being relapse-free in subjects with GCA. Assessment of GC sparing strategies in GCA has long depended on imprecise trials that would change significance if outcomes were reversed for a handful of subjects. FI may be used in rheumatology to simplify communication of statistical significance and overcome limitations of p-value.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Alvise MD, Divi MD, PhD, Jose R. MD, MSc, Eric L. MD, MPH, M. Hassan MD, MPH,